Warm autoimmune hemolytic anemia (WAIHA), a type of autoimmune hemolytic anemia, is caused by increased erythrocyte destruction by IgG autoantibodies. Increasing the hemoglobin level to > 10 g/dL is the primary goal of treatment. With no approved drug therapy, corticosteroids, rituximab, and immunosuppressants form the mainstay of treatment for WAIHA. Two oral agents (Rigel’s fostamatinib and Incyte’s parsaclisib) and an antibody (J&J’s nipocalimab) are in Phase III development and lead the race to reach the market for the treatment of WAIHA. With a strong drug pipeline, the treatment landscape for WAIHA is expected to change significantly over the next ten years. The new drugs are not expected to replace the current standard of care, but they will carve out a niche for themselves by targeting certain subpopulation segments. With no approved drugs for WAIHA, drug developers have an opportunity to address this significant unmet need.
Executive Insights provides indication-specific market intelligence with world-class epidemiology, keen insight into current treatment paradigms, biotherapeutic pipelines, key clinical unmet needs, and competitive landscapes, supported by primary and secondary research. This solution provides succinct insights to any biopharma function or business professional looking to quickly grasp a new indication of interest.
GEOGRAPHY: United States, EU5
PRIMARY RESEARCH: 13 KOL interviews from November 2021 to January 2022
KEY COMPANIES COVERED: Janssen Research & Development, Sanofi, Rigel Pharmaceuticals, Incyte, Annexon
KEY DRUGS COVERED: Fostamatinib, nipocalimab, parsaclisib, isatuximab, rilzabrutinib, ANX005